Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies
19.11.2019 16:00:00 EET | Business Wire | Press release
Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to investigate novel biomarkers of response and mechanisms of resistance to cancer therapies. Merck KGaA, Darmstadt, Germany, will utilize Personalis’ newest cancer immunogenomics platform, ImmunoID NeXT™, for clinical biomarker identification and development.
ImmunoID NeXT, through innovative assays and analytics, provides a comprehensive view of each cancer’s genomics and immune microenvironment from a single, limited tumor sample. The platform is an end-to-end solution built for precision oncology biomarker discovery through to clinical applications, enabling simultaneous analysis of cancer mutations, the immune repertoire, neoantigens, tumor escape mechanisms, DNA repair pathways, human leukocyte antigens (including typing, loss of heterozygosity, and somatic mutation detection), tumor mutational burden (TMB), microsatellite instability (MSI), oncoviruses, immune checkpoints, gene expression, immune signatures, and other advanced biomarkers.
“Merck KGaA, Darmstadt, Germany, is a global leader in cancer therapeutic development and we’re thrilled to collaborate with them to identify the next generation of clinical biomarkers for cancer therapies,” said Richard Chen, MD, CSO of Personalis. “We will work with Merck KGaA, Darmstadt, Germany, to leverage the NeXT Platform for novel biomarker identification, analysis of therapy resistance mechanisms, patient stratification, combination therapy strategy, and comprehensive molecular categorization of cancers for enabling precision therapy.”
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of € 14.8 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005366/en/
Contact information
Investor Relations Contact for Personalis:
Caroline Corner
investors@personalis.com
www.westwicke.com
415-202-5678
Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ChipAgents Raises $74M to Scale an Agentic AI Platform to Accelerate Chip Design17.2.2026 17:00:00 EET | Press release
ChipAgents, the category leader for Agentic AI platforms in the semiconductor design industry, announced it has closed an oversubscribed $50 million Series A1 funding round, bringing total capital raised to $74 million. The round was led by Matter Venture Partners, a TSMC-backed HardTech VC firm, with participation from existing investors Bessemer Venture Partners, Micron, MediaTek, and Ericsson. As part of the investment, Wen Hsieh, Founding Managing Partner of Matter VP, will join ChipAgents' Board of Directors, bringing over two decades of expertise and relationships in semiconductor design and manufacturing. Building the AI Workforce for Chip Design Companies This new capital will enable ChipAgents to aggressively scale its Agentic AI platform, expand its engineering and research organization, and accelerate global deployment of multi-agent chip teams. ChipAgents is building the foundational AI infrastructure for chip design, with coordinated AI Agents that can plan, reason, execut
Toshiba Showcases End-to-End Innovations Shaping What’s Next in Retail at EuroShop 202617.2.2026 16:45:00 EET | Press release
At EuroShop 2026, Toshiba Global Commerce Solutions will showcase how retailers across Europe are using scalable, sustainable innovation to address today’s challenges and build what’s next. Exhibiting in Hall 6, Booth C41 from the 22nd to 26th February, Toshiba will demonstrate technologies designed to evolve with retailers, empowering flexibility, resilience, and long-term growth, and prepare them for what’s next. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216755053/en/ At EuroShop, we’re showing how Toshiba empowers retailers across all segments to transform with confidence by scaling intelligent solutions to deliver lasting impact. “Retailers are under pressure to move faster, operate more efficiently, and deliver better experiences than ever before. At EuroShop, we’re showing how Toshiba empowers retailers across all segments to transform with confidence by scaling intelligent, solutions to deliver lasting impact,
Andersen Consulting Expands Executive Talent Capabilities With Lansdowne Executive Search17.2.2026 16:30:00 EET | Press release
Andersen Consulting strengthens its human capital practice through a Collaboration Agreement with Lansdowne Executive Search, a Dublin-based firm specializing in executive search, interim management and board level appointments. Founded in 2015, Lansdowne Executive Search is an Irish-owned firm, delivering C-level executive search, fractional executives, and board placement services. As a partner-led, boutique practice, Lansdowne is known for the deep involvement of senior leadership in all client engagements. Lansdowne helps clients navigate complex leadership transitions and growth strategies across a wide range of sectors including financial services, construction, nonprofit, agriculture, higher education, public sector, and TMT. “Great leadership is contextual and getting it right means understanding far more than just a resume,” said Tom Keane, partner at Lansdowne Executive Search. “Collaborating with Andersen Consulting gives us the scale and access to expertise we need to conti
Caidya Names Michael Clay COO to Drive Operational Excellence and Advance Multi-Regional Clinical Development17.2.2026 16:10:00 EET | Press release
Caidya, a leading global, mid-sized CRO focused on accelerating clinical development for innovative biopharmaceutical companies, today announced the appointment of Michael Clay as chief operating officer (COO). Clay will lead Caidya’s global operational delivery, client engagement model, and execution strategy, further strengthening the company’s ability to serve innovative biopharma sponsors across the U.S., Europe, and Asia-Pacific. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217431202/en/ Michael Clay, Caidya's Chief Operating Officer Clay brings a distinguished track record in global project delivery and site relationship strategy. He has led large-scale global programs across 60+ countries and built high-performing delivery organizations known for operational rigor and sponsor trust. Notably, Clay has extensive leadership experience across Asia-Pacific, where speed, regulatory nuance, and close site collaboration
Gurobi Appoints Dr. Pascal Van Hentenryck to Lead AI Innovation Lab17.2.2026 16:00:00 EET | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce that Dr. Pascal Van Hentenryck has joined the company as head of the Gurobi AI Innovation Lab (GAIL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217170385/en/ Dr. Pascal Van Hentenryck, Head of AI Innovation Lab, Gurobi Optimization As part of Gurobi’s long-term product and technology strategy, the Gurobi AI Innovation Lab is a focused Research & Development initiative dedicated to advancing the combination of multiple AI technologies with optimization to solve complex, large-scale, and time-critical decision problems. “Pascal brings exceptional leadership across mathematical optimization and complementary AI technologies,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “While mathematical optimization remains the best approach for most decision problems—as demonstrated by thousands of successful customer implementatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom